

References

- Ahonen J, and Jokela R, (2005):** Recombinant factor VIIa for life-threatening post-partum haemorrhage. *Br J Anaesth* 94:592–595.
- Aird WC, (2004):** Natural anticoagulant inhibitors: activated protein C. *Best Pract Res Clin Haematol* 17: 161-182.
- Asselta R, Tenchini ML, Duga S.(2007):** Inherited defects of coagulation Factor V: the hemorrhagic side. *J Thromb Haemost.*;5:185-188.
- Aytekin FO and Hunt BJ, (2005):** Recent treatment in DIC. *J Thromb Hemost* 189 (2): 161-66.
- Barash PG, Cullen BF, Stoelting RK, (2001):** Clinical Anesthesia, 4th eds., Lippincott-Williams & Wilkins, Philadelphia, Pp 224-26.
- Bern MM, Newland AC, and Dang QD, (2005):** Treatment of factor XI inhibitor using recombinant activated factor VIIa. *Acta Anesth Scand* 11(1): 20-25
- Bick RL, (1999):** Disseminated intravascular coagulation: objective criteria for diagnosis and management. *Med Clin North Am* (78)51: 1-543.
- Bouma BN, Mosnier LO, (2003):** Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. *Pathophysiol Hemost Thromb* 33: 375-381.
- Broze GJJr, (2003):** The tissue factor pathway of coagulation. In: Loscalzo J, Schafer AI, eds. *Thrombosis and Hemorrhage*, 3rd ed. Philadelphia: Lippincott-Williams&Wilkins, 62-80.

- Catalano PM, and Harrison L, (2001):** The National Medicine Series for independent study. N Engl J Med 163(1): -268
- Chan PN, and Alter B, (2004):** Complication of percutaneous nephrostomy in patient with coagulopathy. Am J Nephrol 77(922): 75-76.
- Cogger VC, and Rogni M, (2007):** Hepatic sinusoidal pseudocapillarization aging Mayoprolifralation proc., 38(10): 1101-107
- Dahlback B, (2008):** Advances in understanding pathogenic mechanisms of thrombophilic disorders. *Blood*. Jul 1 2008;112(1):19-27.
- Deluca B, and Braun WJ, (2004):** Right coronary artery bypass complicated by a cute thrombotic occlusion. Am J Cardiol 5(10): 785-88.
- Dion CA, Chaimberg KH, Gettinger A and Glass DD, (2004):** Perioperative hemostasis and coagulopathy, 45th chapter, In: "Critical Care Medicine and Peri-operative management", 2nd edition, Lippincott-Williams&Wilkins, Philadelphia, New York, London, Volume 2, Pp 549-565.
- Droffler KM, and Melly J, (2002):** Bioavailability of subcutaneous low-molecular weight heparin. Am J Geriatr Soc 359(3): 849-50.
- Ebbesen LS and Raskob GE, (2004):** Thrombosis and vascular biology. J Biol Chem 50(8): 917-30.
- Engstrom M and Glazer CB, (2004):** Thrombocytopenia predicts progressive hemorrhage after head trauma. Crit Care Med 22(2): 291-96.
- Esmon CT, (2003):** The protein C pathway. Chest 124(3 Suppl): 26S-32S.

- Favaloro EJ and Holland PV, (2005):** Diagnostic issues in thrombophilia. *Thromb Res* 31(1): 11-16.
- Forestier F, Belisle S, Contant C, et al., (2001):** Reproducibility and interchangeability of the thromboelastograph, sonoclot and hemochron activated coagulation time in cardiac surgery. *Can J Anesth* 48: 902-10.
- Frederick R and De Moerloose P, (2005):** Modulators of coagulation cascades. *Chin Med Sci J* 12(4): 397-417.
- Friendman RJ and Dunswerth GA, (2006):** Cost analysis of extended prophylaxis with enoxaparine after hip arthroplasty. *Am J Surg* 370(1): 171-82.
- Galan-Roosen AE, (2005):** Risk factor for perinatal mortality with coagulopathy. *Clin Obst Gynecol* 112(3): 306-41.
- George JN, Woolf SH and Raskob GE, (2005):** Recent advances in coagulopathies. *Lancet* 355(9214): 1531-1539.
- Gonado S and Gillis JG, (2004):** Systemic inflammation and DIC. *Crit Care Med* 28(4): 237-44.
- Goyal D and Jaequemin MG, (2005):** Complications of anticoagulants. *J Pharmacol* 17(1): 13-20.
- Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;(2007):**chap 178. Schafer AI. Approach to the patient with bleeding and thrombosis.
- Gurbel, P.A., Becker, R.C., Mann, K.G., Steinhubl, S.R. and Michelson, A.D. (2007)** Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 50: 1822-1834.

- Hassell K, (2005):** The management of patient with heparin-induced thrombocytopenia to require anti-coagulant therapy. *Am J Hematol* 127(2): 1-8.
- Hedner U, (2006):** Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. *J Thromb Hemost* 4: 2498-500.
- Hedner U, and Erhardtsen E (2003):** Potential role of recombinant factor VIIa as a hemostatic agent. *Clin Adv Hematol Oncol* 1: 112-19.
- Horan JT, and Francis CW, (2004):** FDPs, fibrin monomer and soluble fibrin in DIC. *Anesth Analog* 27(3): 657-77.
- Jenny NS, Mann KG, (2003):** Coagulation cascade: an overview. In: "Loscalzo J, Schafer AI, eds. *Thrombosis and Hemorrhage*", 3rd ed. Philadelphia, Lippincott-Williams&Wilkins, 1-21.
- Juckett EC, and Kalama L, (2002):** *Am Fam Physician Lancet* 65(7): 1367-377.
- Kelly R, and Dimo SD, (2006):** Relation between Rheumatological diseases and Coagulopathy. *Am J Rheumatology* 17(4): 1105-119.
- Kessler C. (2007):** Hemorrhagic disorders: coagulation factor deficiencies. In: Goldman L, Ausiello D, eds. *Cecil Medicine*. 23rd ed. Philadelphia, Pa:Saunders Elsevier;2007:chap 180
- Kolev K, Machovich R, (2003):** Molecular and cellular modulation of fibrinolysis. *Thromb Hemost* 89: 610-621.
- Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, et al. (2009)** Emerging clinical concerns in the ageing haemophilia patient. *Haemophilia*. Jul 21 2009

- Konkle BA and Schafer AI, (2006):** Hemostasis, thrombosis, fibrinolysis and C.V diseases in Braunwald's Heart disease, 7th edition, Elsevier-Saunders, Philadelphia, Pp 2067-2092.
- Koster A, Hansen R, Schulz J, et al., (2003):** Assessment of the resonance thromboelastograph C5-3 for differentiation of coagulation disorders: A pilot invitro investigation of simulated post-cardio-pulmonary bypass coagulopathies. J Extra Corp Technol 33: 159-166.
- Laffan M, (2005):** Coagulation. In: "Recent Advances in Anesthesia and Intensive care", 23(3rd chapter): 55-67.
- Levi M and De jonge, 2005):** Disseminated intravascular coagulation. N Engl J Med 341: 586-92.
- Lippi G, Favaloro EJ, Salvagno GL, Franchini M (2009):** Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta. Jul 2009;405(1-2):8-16.
- Mallet SV and Cox DJ, (2004):** Thromboelastography. Br J Anesth 69: 307-13.
- Mann KG, Butenas S, Brummel K, (2003):** The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23: 17-25.
- Martlew VJ, and Machin SJ, (2006):** Preoperative management of patients with coagulation disorders. Br J Anesth 84: 448-55.
- Martlew VJ and Machin SJ, (2006):** Perioperative management of patients with coagulation disorders. Br J Anesth 85(2): 466-55.
- Manco-Johnson M.(2005)** Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr. Feb 2005;17(1):3-6.

- McMillan R and Aronson DL, (2005):** The Role of antiplatelets auto-antibody assays in the diagnosis of DIC and ITP. *Anesth Analg* 4(2): 160- 165.
- Medeiros D and Buchanan GR, (2003):** Idiopathic thrombocytopenic purpura. *Semin Thromb Hemost* 12(1): 4-9.
- Miller RD, (2000):** Transfusion therapy. In: "Anesthesia, by Miller RD eds.", 5th eds., Churchill-Livingstone, Philadelphia, pp 2786-93.
- Nurden AT, Nurden P (2007).** "The gray platelet syndrome: clinical spectrum of the disease". *Blood Rev.* 21 (1): 21–36. doi:[10.1016/j.blre.2005.12.003](https://doi.org/10.1016/j.blre.2005.12.003)..
- Nesheim M, (2003):** Thrombin and fibrinolysis. *Chest* 124(3 Suppl): 33S-39S.
- Nichols WL, Hultin MB, James AH, et al, (2007) :** and the NHLBI von Willebrand Disease Expert Panel. The Diagnosis, Evaluation, and Management of von Willebrand Disease. Bethesda, Md: National Heart, Lung, and Blood Institute. NIH publication no. 08-5832.
- Neuhaus T and Kessler CM, (2002):** Recurrent spontaneous hemorrhage in a patient with recurrent thrombo-cytopenia. *Br J Hematol* 91(4): 112-18.
- Nilesen VG, (2005):** Effects of coagulation factors deficiency on plasma coagulation kinetics. *Br J Hematol* 49(2): 222-31.
- Osterud B and Nizzi FA, (2004):** The tissue factor pathway in DIC. *Crit Care Med* 27(4): 605-17.
- O'Brien S, Tefferi A, Valent P. (2006):** Chronic myelogenous leukemia and myeloproliferative disease. *Hematology (Am Soc Hematol Educ Program)*.;146-62

- Parizck P, and Morris RB, (2004):** Recent advances in DIC. Clin Obst Gynecol 10(12): 887-93.
- Petrovitch T, (2003):** An approach to the patient who may have bleeding disorders. ASA refresher courses, 186: 1-6.
- Pivalizza EG, Pivalizza PT, and Weavina TM, (2003):** Anti-coagulation monitoring. Anesth Analog 15(5): 366-71.
- Ploplis VA, Castellino FJ, (2002):** Gene targeting of components of the fibrinolytic system. Thromb Hemost 87: 22-31.
- Roberts HR,.(2006):** Hemophilia A and hemophilia B. In: Lichtman MA, et al, eds. *Williams Hematology*.7th ed. New York, NY: The McGraw-Hill Companies, Inc.; 2006:chap 115.
- Rodeghiero F, Castaman G, Tosetto A (2009).** How I treat von Willebrand disease. *Blood*. ;114(6):1158-65.
- Sadler JE, (2003):** Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 101: 2089-93.
- Slichter SJ, and Basta SF, (2004):** Factors affecting post-transfusion platelets increments. Hematology 50(5): 37-69.
- Smith G, Rowbothatn DJ and Aitkenhed AR, (2001):** Hematology. In: "Textbook of Anesthesia", 4th eds., Pp 259: 269.
- Stasi R, Evangelista ML, Stipa E, (2008):** Idiopathic thrombocytopenic purpura: current concepts in pathophysiologyand management. *Thromb Haemost.* ;99(1):4-13.
- Smythe MA, Koerber JM, Mattson JC(2007):** The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. *Chest*. Jun 2007;131(6):1644-9.
- Stoelting RK and Dierdorf SF, (2002):** Coagulopathies. In: "Anesthesia and co-existing disease", 4th eds., Churchill-Livingstone, 25th chapter, Pp 489-504.

- Stoelting RK, and Dierdorf SF, (2002):** Handbook for anesthesia and coesiting diseases. Lancet, 2nd eds., 16(3): 1440-46.
- Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, WadaT, (2009):** . Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. *Thromb Res.* Aug 4 2009
- Tumen KF, Spiess PD, McCarthy, et al., (1999):** Comparison of visco-elastic measures of coagulation after CPB. *Anesth Analg* 69: 96.
- Van dervoort PH and Nevelsteen M, (2005):** Nadroparin versus regional heparin-protamine anticoagulation. *J Am Coll Cardiol* 23(3): 175-80.
- Van Winckel M, De Bruyne R, Van De Velde S, et al (2008).** Vitamin K, an update for the paediatrician. *Eur J Pediatr.* Nov 4 2008;
- Waring PH, Shaw DB and Brumfield CG, (2000):** Anesthetic management of a parturient with Osier-Weber-Rendu syndrome and rheumatic heart disease. *Anesth Analg* 71: 96-9.
- Weiler H, (2004):** Mouse models of thrombosis: thrombomodulin. *Thromb Hemost* 92: 467-77.
- Workentin TE and Blesa ES, (2007):** Laboratory testing for heparin-induced thrombocytopenia. *J Thromb Thrombolysis* 10(4): 35-75.
- Yang MY, Pleska B, and Webb SW, (2004):** Clinical manifestation and management of hemophilic patient. *Blood Purif* 10(5): 483-90.